Low Andrea J, Mburu Gitau, Welton Nicky J, May Margaret T, Davies Charlotte F, French Clare, Turner Katy M, Looker Katharine J, Christensen Hannah, McLean Susie, Rhodes Tim, Platt Lucy, Hickman Matthew, Guise Andy, Vickerman Peter
School of Social and Community Medicine, University of Bristol, United Kingdom.
ICAP, Columbia University, New York, New York.
Clin Infect Dis. 2016 Oct 15;63(8):1094-1104. doi: 10.1093/cid/ciw416. Epub 2016 Jun 25.
Human immunodeficiency virus (HIV)-infected people who inject drugs (PWID) frequently encounter barriers accessing and remaining on antiretroviral therapy (ART). Some studies have suggested that opioid substitution therapy (OST) could facilitate PWID's engagement with HIV services. We conducted a systematic review and meta-analysis to evaluate the impact of concurrent OST use on ART-related outcomes among HIV-infected PWID.
We searched Medline, PsycInfo, Embase, Global Health, Cochrane, Web of Science, and Social Policy and Practice databases for studies between 1996 to November 2014 documenting the impact of OST, compared to no OST, on ART outcomes. Outcomes considered were coverage and recruitment onto ART, adherence, viral suppression, attrition from ART, and mortality. Meta-analyses were conducted using random-effects modeling, and heterogeneity assessed using Cochran Q test and I(2) statistic.
We identified 4685 articles, and 32 studies conducted in North America, Europe, Indonesia, and China were included. OST was associated with a 69% increase in recruitment onto ART (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.32-2.15), a 54% increase in ART coverage (odds ratio [OR], 1.54; 95% CI, 1.17-2.03), a 2-fold increase in adherence (OR, 2.14; 95% CI, 1.41-3.26), and a 23% decrease in the odds of attrition (OR, 0.77; 95% CI, .63-.95). OST was associated with a 45% increase in odds of viral suppression (OR, 1.45; 95% CI, 1.21-1.73), but there was limited evidence from 6 studies for OST decreasing mortality for PWID on ART (HR, 0.91; 95% CI, .65-1.25).
These findings support the use of OST, and its integration with HIV services, to improve the HIV treatment and care continuum among HIV-infected PWID.
注射毒品的艾滋病毒感染者(PWID)在获得和维持抗逆转录病毒治疗(ART)方面经常遇到障碍。一些研究表明,阿片类药物替代疗法(OST)有助于PWID参与艾滋病毒服务。我们进行了一项系统评价和荟萃分析,以评估同时使用OST对感染艾滋病毒的PWID与ART相关结局的影响。
我们检索了Medline、PsycInfo、Embase、全球卫生、Cochrane、科学网以及社会政策与实践数据库,查找1996年至2014年11月期间记录OST(与未使用OST相比)对ART结局影响的研究。所考虑的结局包括ART的覆盖范围和招募、依从性、病毒抑制、ART治疗的退出率以及死亡率。使用随机效应模型进行荟萃分析,并使用Cochran Q检验和I²统计量评估异质性。
我们识别出4685篇文章,纳入了在北美、欧洲、印度尼西亚和中国进行的32项研究。OST与ART招募增加69%相关(风险比[HR],1.69;95%置信区间[CI],1.32 - 2.15),ART覆盖范围增加54%相关(优势比[OR],1.54;95% CI,1.17 - 2.03),依从性增加2倍相关(OR,2.14;95% CI,1.41 - 3.26),以及退出率的优势降低23%相关(OR,0.77;95% CI,0.63 - 0.95)。OST与病毒抑制优势增加45%相关(OR,1.45;95% CI,1.21 - 1.73),但仅有6项研究提供的有限证据表明OST可降低接受ART治疗的PWID的死亡率(HR,0.91;95% CI,0.65 - 1.25)。
这些发现支持使用OST及其与艾滋病毒服务相结合,以改善感染艾滋病毒的PWID的艾滋病毒治疗和护理连续性。